Pharma Mar, S.A.
PharmaMar develops and sells cancer medicines inspired by compounds found in marine organisms. It earns revenue from its own drug sales, manufacturing and licensing agreements, and royalties when partners sell its treatments.
Overview
Latest results
Latest financial publication
9M 2026 financial results
Investment Thesis
Commercial medicines alongside clinical risk
European Tech Equities analysis ·
The investment case
The case rests on growing recurring drug sales and royalties while funding new treatments. Zepzelca offers a route to wider commercial reach, but product concentration leaves results sensitive to one medicine’s uptake and competitive position.
Business progress
Nine-month 2026 revenue rose 12% to €146.9 million. Sales plus royalties, the company’s recurring-revenue measure, grew 30% to €137.4 million. These commercial gains coexist with the negative LAGOON outcome; they do not establish success for every clinical programme.
Customer demand
Demand depends on eligible patients, prescribing decisions, reimbursement and competing therapies. Approval allows commercialisation for a specific use; it does not guarantee rapid adoption or the same price in every country.
Financial position
Nine-month net profit was €8.7 million. At September 2026, cash alone was €44.6 million; cash plus financial investments was €176.9 million, against €67.1 million of financial debt excluding leases. Licensing payments and grants make reported profit less predictable than recurring sales.
Value and risks
Separate recurring sales and royalties from upfront licensing income before assessing earnings. Watch commercial uptake, research spending and cash generation together. Trial failures, partner dependence and competing treatments can change the outlook quickly.
What would weaken the case
- Revenue is concentrated in a small number of medicines.
- Trial success and approval cannot be assumed across indications.
- Partner sales, reimbursement and licensing timing affect earnings.
Sources
Financials
The business in numbers
Latest
Income statement
Cash flow
Balance sheet
Sources and details
Each statement retains its reporting period. Charts use comparable periods and a shared accounting basis; a dash means the figure has not been verified on European Tech Equities.
Calculated: margins = profit ÷ revenue; free cash flow = operating cash flow less capital expenditure; net debt uses the issuer-reported measure when supplied, otherwise debt less cash; liabilities = assets less equity. The company-specific notes explain what debt includes. Negative net debt represents net cash. Quarterly flows cover each individual quarter; balance sheet figures are at period end.
Consolidated IFRS figures. Licensing milestones and grants make period comparisons uneven. Cash excludes financial investments included in the company’s broader liquidity figure. Nine-month revenue is the sum of the four revenue lines; small rounding differences exist in the headline summary. Some partner royalties are estimated pending partner reports.
Annual
Income statement
Cash flow
Balance sheet
Sources and details
Each statement retains its reporting period. Charts use comparable periods and a shared accounting basis; a dash means the figure has not been verified on European Tech Equities.
Calculated: margins = profit ÷ revenue; free cash flow = operating cash flow less capital expenditure; net debt uses the issuer-reported measure when supplied, otherwise debt less cash; liabilities = assets less equity. The company-specific notes explain what debt includes. Negative net debt represents net cash. Quarterly flows cover each individual quarter; balance sheet figures are at period end.
Consolidated IFRS figures. Licensing milestones and grants make period comparisons uneven. Cash excludes financial investments included in the company’s broader liquidity figure. Nine-month revenue is the sum of the four revenue lines; small rounding differences exist in the headline summary. Some partner royalties are estimated pending partner reports.
Half-year
Income statement
Cash flow
Balance sheet
Sources and details
Each statement retains its reporting period. Charts use comparable periods and a shared accounting basis; a dash means the figure has not been verified on European Tech Equities.
Calculated: margins = profit ÷ revenue; free cash flow = operating cash flow less capital expenditure; net debt uses the issuer-reported measure when supplied, otherwise debt less cash; liabilities = assets less equity. The company-specific notes explain what debt includes. Negative net debt represents net cash. Quarterly flows cover each individual quarter; balance sheet figures are at period end.
Consolidated IFRS figures. Licensing milestones and grants make period comparisons uneven. Cash excludes financial investments included in the company’s broader liquidity figure. Nine-month revenue is the sum of the four revenue lines; small rounding differences exist in the headline summary. Some partner royalties are estimated pending partner reports.
Year to date
Income statement
Cash flow
Balance sheet
Sources and details
Each statement retains its reporting period. Charts use comparable periods and a shared accounting basis; a dash means the figure has not been verified on European Tech Equities.
Calculated: margins = profit ÷ revenue; free cash flow = operating cash flow less capital expenditure; net debt uses the issuer-reported measure when supplied, otherwise debt less cash; liabilities = assets less equity. The company-specific notes explain what debt includes. Negative net debt represents net cash. Quarterly flows cover each individual quarter; balance sheet figures are at period end.
Consolidated IFRS figures. Licensing milestones and grants make period comparisons uneven. Cash excludes financial investments included in the company’s broader liquidity figure. Nine-month revenue is the sum of the four revenue lines; small rounding differences exist in the headline summary. Some partner royalties are estimated pending partner reports.
Performance
About these figures
Dates link to the original reports. Bars compare the same period a year earlier, on a consistent accounting basis. Arrows show whether the number rose or fell, not whether it is good or bad for the business.
Research & updates
Interviews
Interviews are coming soon
No interviews with Pharma Mar, S.A. have been published yet.
Sources
Sources & data dates
Financial figures link to the company’s publications and retain their reporting period. Share prices have their own closing dates.
9M 2025 · Published Oct 29, 2026 · Checked Nov 15, 2026
9M 2026 · Published Oct 29, 2026 · Checked Nov 15, 2026
H1 2025 · Published Jul 29, 2026 · Checked Nov 15, 2026
H1 2026 · Published Jul 29, 2026 · Checked Nov 15, 2026
FY 2024 · Published Mar 13, 2026 · Checked Nov 15, 2026
FY 2025 · Published Mar 13, 2026 · Checked Nov 15, 2026
Checked 2026-11-15
Checked 2026-11-15
Checked 2026-11-15
